UBS Group Portfolio holdings
UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UBS Group
UBS
|
+$1.48B |
| 2 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$690M |
| 3 |
VanEck Junior Gold Miners ETF
GDXJ
|
+$588M |
| 4 |
Truist Financial
TFC
|
+$532M |
| 5 |
VanEck Gold Miners ETF
GDX
|
+$278M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.3B |
| 2 |
Alibaba
BABA
|
+$771M |
| 3 |
AABA
Altaba Inc
AABA
|
+$759M |
| 4 |
STI
SunTrust Banks, Inc.
STI
|
+$503M |
| 5 |
BPL
Buckeye Partners, L.P.
BPL
|
+$467M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 9.82% |
| 2 | Financials | 7.38% |
| 3 | Healthcare | 6.65% |
| 4 | Consumer Discretionary | 5.46% |
| 5 | Industrials | 5.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4626
Insmed
INSM
$29B
| $633K | ﹤0.01% |
26,515
-189,140
| -88% | -$3.85M |
|
|
OPLN
4627
Openlane
OPLN
$4.48B
| $633K | ﹤0.01% |
29,069
-81,727
| -74% | -$1.86M |
|
4628
BridgeBio Pharma
BBIO
$16.4B
| $632K | ﹤0.01% |
18,041
-15,658
| -46% | -$434K |
|
4629
Prothena Corp
PRTA
$473M
| $631K | ﹤0.01% |
39,856
-20,676
| -34% | -$222K |
|
|
BFY
4630
DELISTED
BlackRock New York Municipal Income Trust II
BFY
| $631K | ﹤0.01% |
43,739
+1,821
| +4% | +$26.1K |
|
4631
Addus HomeCare
ADUS
$2.18B
| $630K | ﹤0.01% |
6,480
+5,198
| +405% | +$458K |
|
4632
Forrester Research
FORR
$225M
| $630K | ﹤0.01% |
15,117
+6,878
| +83% | +$256K |
|
4633
Hanmi Financial
HAFC
$948M
| $628K | ﹤0.01% |
31,403
+4,513
| +17% | +$87.1K |
|
4634
UNIFI
UFI
$129M
| $627K | ﹤0.01% |
24,812
+6,900
| +39% | +$167K |
|
|
DCPH
4635
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $625K | ﹤0.01% |
10,054
-46,875
| -82% | -$2.23M |
|
4636
ePlus
PLUS
$2.32B
| $624K | ﹤0.01% |
14,800
-434
| -3% | -$17.7K |
|
|
SCTL
4637
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $624K | ﹤0.01% |
34,073
+14,252
| +72% | +$205K |
|
4638
Xtrackers MSCI All World ex US Hedged Equity ETF
DBAW
$303M
| $622K | ﹤0.01% |
21,512
-2,701
| -11% | -$76.7K |
|
4639
Atara Biotherapeutics
ATRA
$80.6M
| $621K | ﹤0.01% |
1,508
-251
| -14% | -$86.5K |
|
4640
Live Oak Bancshares
LOB
$1.98B
| $621K | ﹤0.01% |
32,644
+3,046
| +10% | +$56.3K |
|
4641
Cadiz
CDZI
$299M
| $620K | ﹤0.01% |
56,273
+17,039
| +43% | +$197K |
|
|
DWIN
4642
DELISTED
Invesco DWA Tactical Multi-Asset Income ETF
DWIN
| $620K | ﹤0.01% |
24,197
-2,218
| -8% | -$56.5K |
|
4643
PUT
Barclays
BCS
$93.7B
| $619K | ﹤0.01% |
65,000
| – | – |
|
4644
Krystal Biotech
KRYS
$9.68B
| $619K | ﹤0.01% |
11,174
-21,394
| -66% | -$1.05M |
|
4645
Invesco FTSE RAFI Developed Markets ex-US Small-Mid ETF
PDN
$365M
| $619K | ﹤0.01% |
19,375
-38,042
| -66% | -$1.17M |
|
4646
Veracyte
VCYT
$3.73B
| $619K | ﹤0.01% |
22,167
-66,056
| -75% | -$1.71M |
|
|
CATC
4647
DELISTED
CAMBRIDGE BANCORP
CATC
| $619K | ﹤0.01% |
7,723
+994
| +15% | +$77.5K |
|
4648
Digimarc Corp
DMRC
$172M
| $618K | ﹤0.01% |
18,394
+6,048
| +49% | +$217K |
|
4649
Weyco Group
WEYS
$448M
| $616K | ﹤0.01% |
23,287
-6,858
| -23% | -$169K |
|
4650
CALL
Fox Class A
FOXA
$26.1B
| $615K | ﹤0.01% |
16,600
-1,197,400
| -99% | -$41M |
|
Similar funds
UBS Group's Q4 2019 Portfolio in Review
As of Q4 2019, UBS Group held 8,864 positions worth $287B, up 11% from $260B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
UBS Group's Q4 2019 filing shows 808 new, 4,306 increased, 2,684 reduced and 688 closed positions. Its largest new stake was Bristol-Myers Squibb Company Contingent Value Rights: 5,302,748 shares worth $16M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.3B.
By sector, the portfolio is most concentrated in Technology at 9.8% of assets, up from 9.5% a quarter earlier, followed by Financials and Healthcare.
- UBS Group's largest Q4 2019 buy was Bristol-Myers Squibb Company Contingent Value Rights: 5,302,748 shares worth $16M.
- UBS Group added most to UBS Group in Q4 2019, an estimated $1.48B increase.
- UBS Group's biggest Q4 2019 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.3B.
- UBS Group fully exited Altaba Inc in Q4 2019, selling an estimated $759M.
- UBS Group's ten largest holdings make up 13% of its $287B portfolio in Q4 2019.
- UBS Group opened 808 new positions and closed 688 in Q4 2019.
- UBS Group's portfolio value rose 11% quarter-over-quarter to $287B.
Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.